سعر كيناكومب مرهم موضعي 30 جم 2024

Kenacomb topical ointment 30 g by SmithKline Beecham (Egypt): combination of triamcinolone acetonide (corticosteroid), neomycin and gramicidin (antibacterials) and nystatin (antifungal).

• Topical management of corticosteroid-sensitive cutaneous conditions infected or likely to be infected by organisms sensitive to the anti-infectives present.Health Products Regulatory Authority (HPRA, Ireland; formerly Irish Medicines Board)

• Irritation, impaired healing, petechiae and ecchymoses, facial erythema, increased sweating, hirsutism, acneiform eruptions, skin thinning/atrophy, purpura, striae, telangiectasia, sensitivity reactions, and ototoxicity and nephrotoxicity with prolonged use.International label, equivalent formulation · Health Products Regulatory Authority (HPRA, Ireland; formerly Irish Medicines Board)

• Tuberculous and viral lesions of the skin; fungal lesions not susceptible to nystatin.International label, equivalent formulation · Health Products Regulatory Authority (HPRA, Ireland; formerly Irish Medicines Board)
• Hypersensitivity to any of the components.International label, equivalent formulation · Health Products Regulatory Authority (HPRA, Ireland; formerly Irish Medicines Board)
• Should not be used for facial rosacea, acne vulgaris or perioral dermatitis.International label, equivalent formulation · Health Products Regulatory Authority (HPRA, Ireland; formerly Irish Medicines Board)

• Prolonged use may result in superinfection with resistant organisms, including fungi. Avoid continuous treatment for longer than three weeks in children under three years (adrenocortical suppression, growth retardation).International label, equivalent formulation · Health Products Regulatory Authority (HPRA, Ireland; formerly Irish Medicines Board)
• Use with caution and in small amounts on extensive burns, trophic ulcers or denuded skin where neomycin absorption is possible; neomycin may cause irreversible deafness, especially with renal/hepatic impairment or in the elderly.International label, equivalent formulation · Health Products Regulatory Authority (HPRA, Ireland; formerly Irish Medicines Board)
• Do not continue steroid-antibiotic combinations for more than 7 days without clinical improvement; extended or recurrent use increases contact sensitisation risk; prolonged corticosteroid use may be associated with cataracts.International label, equivalent formulation · Health Products Regulatory Authority (HPRA, Ireland; formerly Irish Medicines Board)

• Inadequate evidence of safety in human pregnancy; topical corticosteroids in pregnant animals caused fetal abnormalities (cleft palate, growth retardation) and there are theoretical risks of neomycin ototoxicity; use with caution only when benefit outweighs risk.International label, equivalent formulation · Health Products Regulatory Authority (HPRA, Ireland; formerly Irish Medicines Board)
• It is not known whether any of the components are excreted in breast milk.International label, equivalent formulation · Health Products Regulatory Authority (HPRA, Ireland; formerly Irish Medicines Board)

English text not available for this section.